accountVenture capital boost made to bolster R&D BEIJING - Multinational drugmaker Eli Lilly and Co said on Tuesday it will continue its venture capital investment in China's biopharmaceutical industry. The move will to strengthen its research...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Lilly to continue China expansion
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account